A recent study suggests that patients who stop using popular weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who halt traditional diet and exercise plans.
Published data in a leading health publication demonstrates that while overweight individuals can lose a large proportion of their total mass while on the medication, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Users using these drugs must be cognizant of the risk of quick weight regain when the medication is stopped," cautioned expert Dr. Susan Jebb.
Such speed of recovery suggests a reversion to original weight within about a year and a half.
Comparing Approaches
The study, which looked at 37 of trials involving thousands of patients, contrasted the results of GLP-1 agonists with other pills.
The team point out that people who shed pounds through lifestyle changes alone usually see a more gradual weight regain—approximately 0.1 kg a month—after stopping.
Explaining the Quick Regain
Experts believe the mode of action of the drugs is key to understanding the heightened rebound.
The injections mimic a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels several times higher than normal may cause the system to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication means appetite is uncontrolled, making overeating a significant risk."
An Ongoing Condition?
Health authorities suggest the injections for individuals with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals argue that, considering the likelihood of weight regain, the treatment is often long-term.
This perspective is supported by drug manufacturers, who state that the findings "highlight the long-term nature of excess weight," akin to managing diseases like diabetes.
User Experiences
People who have come off the jabs report a intense resurgence of cravings.
"I experienced something activating and you're instantly extremely hungry," recalled a patient.
This challenge is exacerbated if users have not developed sustainable lifestyle or habit modifications during therapy.
Growing Adoption
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is more common among women than males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Ultimately, researchers caution that while GLP-1 drugs are potent tools for weight loss, they are not a permanent solution and maintained weight loss relies on combined lifestyle support.
